Last reviewed · How we verify

Aldurazyme — Competitive Intelligence Brief

Aldurazyme (LARONIDASE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]. Area: Metabolic.

marketed Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] Metabolic Enzyme Live · refreshed every 30 min

Target snapshot

Aldurazyme (LARONIDASE) — BioMarin. Aldurazyme breaks down abnormal sugar molecules in the body to treat Mucopolysaccharidosis I.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aldurazyme TARGET LARONIDASE BioMarin marketed Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] 2003-01-01
Rhgalns ELOSULFASE ALFA BioMarin marketed Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] N-acetylgalactosamine-6-sulfatase 2014-01-01
Elaprase IDURSULFASE Takeda marketed Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] 2006-01-01
Aryplase GALSULFASE BioMarin marketed Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] 2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] class)

  1. BioMarin · 3 drugs in this class
  2. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aldurazyme — Competitive Intelligence Brief. https://druglandscape.com/ci/laronidase. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: